First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

Phenotypic variables such as smoking history and occupational exposures were significators predictors of head and neck cancer risk.

BioAtla Inc (BCAB) showcases significant advancements in clinical trials while navigating financial hurdles and seeking strategic partnerships.

Immutep's eftilagimod shows promising results in head and neck ... The positive TACTI-003 readout strengthens my "Buy" sentiment, though risks remain in this challenging cancer treatment landscape.

Early stage diagnosis offers the most favorable prognosis for cancer treatment. Although conventional screening methods ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

"It is very exciting to see this first positive trial of upfront immunotherapy moving forward with the potential to become the new standard of care for patients with head and neck cancer worldwide ...

head and neck surgical oncologist, Dana-Farber Cancer Institute, Boston, at the American Association for Cancer Research (AACR) Annual Meeting 2025. Pembrolizumab — which already carries ...